- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Alliance begins Imagent phase III trials
Alliance Pharmaceutical has announced that phase III clinical trials have commenced on its Imagent ultrasound contrast agent. Imagent, formerly known as AF0150, will be investigated for its ability to aid in the evaluation of cardiac function as assessed
Alliance Pharmaceutical has announced that phase III clinical trials have commenced on its Imagent ultrasound contrast agent. Imagent, formerly known as AF0150, will be investigated for its ability to aid in the evaluation of cardiac function as assessed by both ejection fraction and endocardial border definition.
In separate research, Imagent is also being targeted for improving the detection of blood-flow abnormalities and solid tumors in organs and glands such as the liver, kidney, breast, and prostate, according to the San Diego-based developer. The microbubble-based agent is under joint development by Alliance and Schering, which has exclusive marketing rights to Imagent (SCAN 8/20/97).
In other news, Alliance reported April 7 that it has received a patent for harmonic imaging with second-generation microbubble contrast agents. In addition to covering harmonic imaging with Imagent, the company claims that the patent also covers agents using any one of a number of fluorocarbon gases. Alliance said the patent was its second for harmonic imaging technology.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
